๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

O-0029 * FOLFIRI PLUS CETUXIMAB VERSUS FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF KRAS-WILDTYPE METASTATIC COLORECTAL CANCER: GERMAN AIO STUDY KRK-0306 (FIRE-3)

โœ Scribed by Modest, D.; von Weikersthal, L. F.; Stintzing, S.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al Batran, S.-E.; Heintges, T.; Lerchenmuller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Muller, S.; Schafer, B.; Jung, A.; Heinemann, V.

Book ID
121857257
Publisher
Oxford University Press
Year
2013
Tongue
English
Weight
33 KB
Volume
24
Category
Article
ISSN
0923-7534

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

FOLFIRI plus cetuximab versus FOLFIRI pl
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
โœ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa ๐Ÿ“‚ Article ๐Ÿ“… 2014 ๐Ÿ› Lancet Publishing Group ๐ŸŒ English โš– 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow